To address this and other recent advances in the genomic understanding of myeloma, the most recent International Myeloma Society risk stratification published in 2025 classifies high-risk myeloma as having a deletion of chromosome 17p or TP53 mutation, as well as biallelic deletion of chromosome 1p.62 Here, TP53 is linked to plasma cell myeloma.